Next Article in Journal
Astrocytes in Flavivirus Infections
Next Article in Special Issue
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
Previous Article in Journal
Accessibility of Cations to the Selectivity Filter of KcsA in the Inactivated State: An Equilibrium Binding Study
Previous Article in Special Issue
mTOR Inhibitors in Advanced Biliary Tract Cancers
Open AccessReview

Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels

by 1,2,†, 2,† and 3,4,5,6,*
Clinical Institute of Pathology, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, 3100 St. Pölten, Austria
Department Life Sciences, IMC University of Applied Sciences Krems, 3500 Krems, Austria
Department of Pathology, Medical Faculty, Otto-von-Guericke University Magdeburg, 39106 Magdeburg, Germany
Department of Pathology, Neuropathology, and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria
Department of Neuropathology, Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Medical University of Graz, 8036 Graz, Austria
German Center for Neurodegenerative Diseases (DZNE), 39120 Magdeburg, Germany
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(3), 690;
Received: 16 January 2019 / Revised: 28 January 2019 / Accepted: 29 January 2019 / Published: 5 February 2019
(This article belongs to the Special Issue mTOR in Human Diseases)
The mTOR pathway is in the process of establishing itself as a key access-point of novel oncological drugs and targeted therapies. This is also reflected by the growing number of mTOR pathway genes included in commercially available next-generation sequencing (NGS) oncology panels. This review summarizes the portfolio of medium sized diagnostic, as well as research destined NGS panels and their coverage of the mTOR pathway, including 16 DNA-based panels and the current gene list of Foundation One as a major reference entity. In addition, we give an overview of interesting, mTOR-associated somatic mutations that are not yet incorporated. Especially eukaryotic translation initiation factors (eIFs), a group of mTOR downstream proteins, are on the rise as far as diagnostics and drug targeting in precision medicine are concerned. This review aims to raise awareness for the true coverage of NGS panels, which should be valuable in selecting the ideal platform for diagnostics and research. View Full-Text
Keywords: mTOR; NGS; illumina; IonTorrent; eIFs mTOR; NGS; illumina; IonTorrent; eIFs
Show Figures

Figure 1

MDPI and ACS Style

Seeboeck, R.; Sarne, V.; Haybaeck, J. Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels. Int. J. Mol. Sci. 2019, 20, 690.

AMA Style

Seeboeck R, Sarne V, Haybaeck J. Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels. International Journal of Molecular Sciences. 2019; 20(3):690.

Chicago/Turabian Style

Seeboeck, Rita; Sarne, Victoria; Haybaeck, Johannes. 2019. "Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels" Int. J. Mol. Sci. 20, no. 3: 690.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop